Keytruda shows nearly 40% CR in high-risk non-muscle invasive bladder cancer unresponsive to standard of care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Merck announced the first presentation of results from an interim analysis of KEYNOTE-057, a phase II trial evaluating Keytruda (pembrolizumab) for previously treated patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ or CIS plus papillary disease (Cohort A).

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

“We’ve always argued that money comes and goes, but if you lose a generation of scientists—you can’t buy them back,” said Kelvin Lee, director of the Indiana University Simon Comprehensive Cancer Center. 
Joni D. Nelson, assistant director for the Office of Workforce Development at the MUSC Hollings Cancer Center, remembers the exact day a switch went off in her head and her career took a turn towards finding ways to improve public health.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login